Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2510-3636
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report ; volume:6 ; number:1 ; day:13 ; month:12 ; year:2022 ; pages:1-7 ; date:12.2022
European journal of hybrid imaging ; 6, Heft 1 (13.12.2022), 1-7, 12.2022
- Urheber
-
Boughdad, Sarah
Mota, Michael Da
Mendes De Carvalho, Mélanie
Firsova, Maria
Prior, John O.
Schaefer, Niklaus
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s41824-022-00157-y
- URN
-
urn:nbn:de:101:1-2023021909110440876912
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Boughdad, Sarah
- Mota, Michael Da
- Mendes De Carvalho, Mélanie
- Firsova, Maria
- Prior, John O.
- Schaefer, Niklaus
- SpringerLink (Online service)
Ähnliche Objekte (12)
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Einfluss der Peptid-Radio-Rezeptor-Therapie mittels 90Y- und 177Lu-DOTATATE auf die inflammatorische Atheroskleroseaktivität : Therapiemonitoring mittels serieller 68Ga-DOTATATE Positronenemissionstomographie, Computertomographie
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days
The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Einfluss der Peptid-Radio-Rezeptor-Therapie mittels 90Y- und 177Lu-DOTATATE auf die inflammatorische Atheroskleroseaktivität : Therapiemonitoring mittels serieller 68Ga-DOTATATE Positronenemissionstomographie, Computertomographie
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days
The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Einfluss der Peptid-Radio-Rezeptor-Therapie mittels 90Y- und 177Lu-DOTATATE auf die inflammatorische Atheroskleroseaktivität : Therapiemonitoring mittels serieller 68Ga-DOTATATE Positronenemissionstomographie, Computertomographie
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days